According to the Zhitong Finance App, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of the company, received the approval and issuance of the “Chemical Ingredient Drug Marketing Application Approval Notice” (acceptance number: CYHS2060492) for telibapressin acetate with a specification of 30g/piece from the China Drug Administration.
According to reports, the raw material of teripressin acetate is used in the production of injectable teribapressin preparations. Teripressin is a synthetic vasopressin analog. It is a vasoconstrictor drug among vasoactive drugs. It is mainly used to stop bleeding from cirrhosis, varicose veins, and bleeding. Currently, it is widely used clinically in the treatment of hepatorenal syndrome, cirrhosis, ascites, infectious shock, burns, acute liver failure, cardiac arrest, etc.